

DAFTAR PUSTAKA

- Al-Owaidi D, Algazally M, Alawaad A. Correlation of serum concentration cyclin-dependent kinase 4 and cyclin-dependent kinase 6 with breast cancer in Babylon province. *Med J Babylon*. 2020;17(2):199.
- Asghar, U., Agnieszka K., Witkiewicz A., Turner N., & Erik S. Knudsen. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapys. *Nat Rev Drug Discov*; 14(2): 130-146. doi:10.1038/nrd4504
- Baker Stacey J, Paulikakos Poulikos I, Irie Hanna Y, Prekh Samir, Rendy E. Premkumar, CDK4: a master regulator of the cell cycle and its role in cancer, *Ganes and Cancer*, Vol 13; 2022
- Bockstaele, L., Bisteau, X., Paternot, S., & Roger, P. P. (2009). Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation. *Molecular and Cellular Biology*, 29(15), 4188–4200. <https://doi.org/10.1128/mcb.01823-08>
- Chen TJ, Lee YY, Li CF. P210 Cyclin-dependent kinase 4 overexpression confers an independent prognosticator of nasopharyngeal carcinoma. *European Journal of Cancer*. 2014 May;50:e68.
- Cocco Emiliano, Lopez Salvatore, Santin Alesandro, Scaltriti Maurizio. Prevalence and role of HER2 mutations in cancer. *Pharmacol Ther*. July 2019 ; 199: 188–196. doi:10.1016/j.pharmthera.2019.03.010. 2019
- Collins, L. C. (2018) ‘Breast’, in Goldblum, J. R. et al. (eds) *Rosai and Ackerman’s Surgical Pathology*. 11th edn. Philadelphia: Elsevier, pp. 1434–1529.
- Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. (December 1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. *Science*. 230 (4730): 1132–1139.
- Debarati, D. and Jihe, Z. (2013) ‘The Role of Chemokine Receptors CXCR4 in Breast Cancer Metastasis’, *Review Article*, pp. 46–57.
- Fassl Anne, et all. CDK4 and CDK6 kinases: from basic science to cancer therapy. *Science*. 2022 January 14; 375(6577): eabc1495. doi:10.1126/science.abc1495.

- Ghafouri-Fard S, Khoshbakht T, Hussien BM, et al. A review on the role of cyclin dependent kinases in cancers. *Cancer Cell International*. 2022;22(1). doi:10.1186/s12935-022-02747-z
- Ginter Paula S, et al. Histologic Grading of Breast Carcinoma: A Multi-Institution Study of Interobserver Variation Using Virtual Microscopy. *National Library of Medicine, Mod Pathol*. 2020 Oct 19;34(4):701–709. doi: 10.1038/s41379-020-00698-2
- Glaviano A, Wander SA, Baird RD, Yap KCH, Lam HY, Toi M, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. *Drug Resistance Updates*. 2024 Sep;76:101103.
- Globocan. (2020) ‘Breast Cancer – The Global Cancer Observatory’.
- Goel Shom, et al. CDK4/6 inhibition in cancer: beyond cell cycle arrest. *Trends Cell Biol*. 2018 November ; 28(11): 911–925. doi:10.1016/j.tcb.2018.07.002.
- Harbour JW et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell* 98 (6), 859–69. 1999; PubMed: 10499802
- Hiebert SW et al. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. *Genes Dev* 6 (2), 177–85. 1992; PubMed: 1531329
- Hsu JL, Hung MC (2016). The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. *Cancer and Metastasis Reviews*. 35 (4): 575–588. doi:10.1007/s10555-016-9649-6. PMC 5215954. PMID 27913999.
- Iqbal Nida, Iqbal Naveed (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications *Reviews journal. Hindawi Publishing Corporation Molecular Biology International*. Volume 2014, Article ID 852748, 9 pages. <http://dx.doi.org/10.1155/2014/852748>
- Juric, Viktorija. & Brona Murphy. (2019). Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. *Journal of Cancer Drug Resist* 3:48-62 <http://dx.doi.org/10.20517/cdr.2019.105>
- Kementerian kesehatan (2018). Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/414/2018 tentang pedoman nasional pelayanan kedokteran tata laksana kanker payudara.
- Kim Sungsoo, CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell cycle commitment and G1/S transitio. *Scientific Reports*. 2022; 12:16810. <https://doi.org/10.1038/s41598-022-20769-5>

- Kumar, Abbas, Aster. et al. (2018) 'The Breast' , in Susan, C.L. (eds). Robbin and Cotran Pathologic Basis of Disease. 9th edn. Philadelphia: Elsevier, pp.1051–1056.
- Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. *Breast Cancer Res Treat.* 2017 Nov;166(1):41–54.
- Malumbres Marcos. (2014) 'Cyclin dependent Kinases', Protein Family Review. Available at: <http://genomebiology.com/2014/15/6/122>
- Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. *Current Opinion in Oncology.* 2014 Nov;26(6):568–75.
- O'Leary B et al. Treating cancer with selective CDK4/6 inhibitors. 2016; *Nat Rev Clin Oncol* 13 (7), 417–30. [PubMed: 27030077]
- O'Sullivan Ciara C, Suman Vera J. Goetz Matthew P., The emerging role of CDK4/6i in HER2-positive breast cancer. *Therapeutic Advances in Medical Oncology.* Vol 11: 1-10, 2019. 2019, Vol. 11: 1–10 DOI: 10.1177/1758835919887665
- Önder T, Ateş Ö, Öner İ, Karaçin C. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study. *International Journal of Clinical Oncology* [Internet]. 2024 Apr 30;29(7):972–84. Available from: <https://doi.org/10.1007/s10147-024-02528-w>
- Ouyang Zhuqing, Qi Jiating, Targeting CDK4/6 for Anticancer Therapy. *Encyclopedia.pub.* Subjects: Biology:Cell Biology: Biochemistry & Molecular Biology
- Podoll, Mirna B and Reisenbichler ES, Stains & CD markers HER2 (c-erbB2) breast. (Last update 2023). Available at: <https://www.pathologyoutlines.com/topic/stainsbreastHER2.html>
- Rahman, M. and Mohammed, S. (2015) 'Breast cancer metastasis and the lymphatic system (Review)', *Oncology Letters*, 10(3), pp. 1233–1239. doi: 10.3892/ol.2015.3486.
- Rakha, E., Allison, K., Bu, H., et al. (2019) 'Invasive Breast Carcinoma of No Special Type', in Lokuhetty, D. et al. (eds) *WHO Classification of Tumours Breast Tumours*. 5th ed. France: International Agency for Research on Cancer (IARC), pp. 102–109.
- Rakha, E., Allison, K., Ellis, I. et al. (2019) 'Invasive Breast Carcinoma: General Overview', in Lokuhetty, D. et al. (eds) *WHO Classification of Tumours Breast Tumours*. 5th edn. France: International Agency for Research on Cancer (IARC), pp. 82–101.

- Roy V, Perez EA (November 2009). Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. (<https://doi.org/10.1634/theoncologist.2009-0142>). The Oncologist. 14 (11): 1061–1069. doi:10.1634/theoncologist.2009-0142
- Saidy B, Rakha EA, Green AR, Ellis IO, Martin SG, Storr SJ. Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. J Cellular Molecular Medi. 2020 Jun;24(11):6263–71.
- Salomon Tadesse, Yu Mingfeng, Kumarasiri Malika, Le Bich Thuy, Wang Shudong, Targeting CDK6 in cancer: State of the art and new insights. Tylor and Francis group, LLC : Cell Cycle, Vol 14 issue 20; Oktober 2015.
- Shanabag A, Armand J, Son E, Yang HW. Targeting CDK4/6 in breast cancer. Experimental & Molecular Medicine [Internet]. 2025 Feb 10; Available from: <https://doi.org/10.1038/s12276-025-01395-3>
- Shao Y, Luo Z, Yu Y, Chen Q, He Y, Liu C, et al. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study. Frontiers in Endocrinology [Internet]. 2022 Aug 18;13. Available from: <https://doi.org/10.3389/fendo.2022.1000704>
- Sinclair William D, Cui Xiaoyan, The Effects of HER2 on CDK4/6 Activity in Breast Cancer, Clinical Breast Cancer, Vol 22, Issue 3, April 2022. <https://doi.org/10.1016/j.clbc.2021.08.007>
- Wang G, Zheng L, Yu Z, Liao G, Lu L, Xu R, et al. Increased cyclin-dependent kinase 6 expression in bladder cancer. Oncology Letters. 2012 Jul;4(1):43–6.
- Wang Xueqing, Zhao Shanshan, Xin Qinghan, Zhang Yunkun, Wang Kainan, Li Man, Recent progress of CDK4/6 inhibitors' current practice in breast cancer. Cancer gene therapy, Vol 31: 1283–1291; 2024)
- Wayan, S. and Wayan, P. S. Y. (2013) 'C-X-C Receptor 4 (CXCR4) Metastasis Kanker Payudara', pp. 126 –131. doi: 10.24293/ijcpml.v19i2.1068. Wikipedia, HER2. Available at: <https://en.wikipedia.org/wiki/HER2>
- Weintraub SJ et al. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375 (6534), 812–5. 1995; PubMed: 7596417
- World Health Organization. Clasification of Tumour of The Eye and Orbit. Fifth Edition Vol 13. 2023
- Yousuf Mohd, Alam M, Shamsi A, Khan P, Hasan GM, Rizwanul Haque QM, et al. Structure-guided design and development of cyclin-dependent kinase

4/6 inhibitors: A review on therapeutic implications. *International Journal of Biological Macromolecules*. 2022 Oct;218:394–408.

Zhang C, Zhou F, Zou J, Fang Y, Liu Y, Li L, et al. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer. *Frontiers in Oncology* [Internet]. 2024 Jan 16;13. Available from: <https://doi.org/10.3389/fonc.2023.1322078>

Zhou Y, Shen JK, Yu Z, Hornicek FJ, Kan Q, Duan Z. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*. 2018 May;1864(5):1573–82.

Ziegler DV, Parashar K, Fajas L. Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. *Seminars in Cancer Biology* [Internet]. 2023 Dec 20;98:51–63. Available from: <https://doi.org/10.1016/j.semcancer.2023.12.002>